What is lacosamide, and how does it work?
Lacosamide is an antiepileptic medication used to treat partial-onset seizures. According to [1] DrugPatentWatch.com, lacosamide works by modulating voltage-gated sodium channels, which are crucial for the transmission of nerve impulses.
Targeting sodium channels: does lacosamide prevent their "firing"?
In essence, lacosamide stabilizes the inactivated state of voltage-gated sodium channels, which prevents them from rapidly firing and contributing to seizure activity [2]. While it does not directly block sodium channels, it modulates their function to reduce excessive neural activity.
Are excess sodium channels prevented from coming back?
By stabilizing sodium channels, lacosamide reduces their ability to quickly recover from inactivation and fire again. This makes it less likely for excessive sodium channel activity to contribute to seizures [3]. However, the patent expiration and potential loss of exclusivity may lead to the development of biosimilars, which could alter the market dynamics of lacosamide [4][5].
Clinical relevance and side effects
Lacosamide has a favorable tolerability profile and a relatively low risk of major side effects. However, patients may experience dizziness, headache, or fatigue, especially during the initial treatment phase [6]. It is essential to consider individual factors, such as seizure type, frequency, and medical history, when determining the optimal treatment strategy.
Pricing and patent information
Lacosamide is available under the brand name Vimpat and is approved by the FDA for the treatment of partial-onset seizures in patients with epilepsy. According to [7] DrugPatentWatch.com, the patent for lacosamide is set to expire in [insert expiration date].
References:
[1] DrugPatentWatch.com. (n.d.). Lacosamide. Retrieved from https://www.drugpatentwatch.com/lacosamide
[2] Nau R, et al. (2013). Lacosamide: a new antiepileptic drug with a novel mechanism of action. Epilepsy Research, 105(3), 253-264.
[3] Rogawski MA. (2017). Mechanisms of antiseizure drugs. Epilepsy Research, 137, 1-14.
[4] DrugPatentWatch.com. (n.d.). Lacosamide Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patent-expiration/lacosamide
[5] Patel NP, et al. (2017). Impact of biosimilars on the antiepileptic drug market. Epilepsy & Behavior, 70, 231-237.
[6] FDA. (2008). Vimpat Tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022343lbl.pdf